Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging.

BACKGROUND Elevated plasma total homocysteine concentration may be a risk factor for cognitive decline and Alzheimer disease, but data from prospective studies are limited. Further, high homocysteine levels are associated with low vitamin status, and it is unknown whether it is homocysteine toxicity or vitamin insufficiency that is responsible for the observed cognitive dysfunction. METHODS We performed cross-sectional and longitudinal analyses of a cohort of 499 high-functioning community-dwelling persons aged 70 to 79 years to determine the effect of homocysteine and related vitamin plasma concentrations on cognitive function and cognitive decline. Nonfasting plasma concentrations of homocysteine, folate, vitamin B(6), and vitamin B(12) were measured at baseline. Summary measures of cognitive function were created from tests of multiple cognitive domains administered at baseline and again after 7 years. RESULTS In cross-sectional analyses investigating each variable separately, subjects with elevated homocysteine levels, or low levels of folate or vitamin B(6), demonstrated worse baseline cognitive function. In longitudinal analyses, after adjusting for multiple covariates, including homocysteine, those in the bottom quartile of folate had a 1.6-fold increased risk (95% confidence interval: 1.01 to 2.31; P =0.04) of being in the worst quartile of 7-year cognitive decline. Low folate levels largely accounted for a trend towards greater cognitive decline with elevated homocysteine level. CONCLUSION In high-functioning older adults, low folate levels appear to be a risk factor for cognitive decline. The risk of developing cognitive decline might be reduced through dietary folate intake.

[1]  P. Ueland,et al.  Total homocysteine in plasma or serum: methods and clinical applications. , 1993, Clinical chemistry.

[2]  M. Soyka,et al.  Dementia associated with vitamin B(12) deficiency: presentation of two cases and review of the literature. , 2000, The Journal of neuropsychiatry and clinical neurosciences.

[3]  Santhosh K. P. Kumar,et al.  Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[4]  T. Seeman,et al.  Homocysteine levels and decline in physical function: MacArthur Studies of Successful Aging. , 2002, The American journal of medicine.

[5]  D. Weir,et al.  Brain function in the elderly: role of vitamin B12 and folate. , 1999, British medical bulletin.

[6]  G. Kaplan,et al.  Book Review of Cornoni-Huntley J, Brock DW, Ostfeld AW, et al. Established populations for epidemiologic studies of the elderly: resource data book , 1987 .

[7]  I. Rosow,et al.  A Guttman health scale for the aged. , 1966, Journal of gerontology.

[8]  M. Albert,et al.  Cognitive performance in a high-functioning community-dwelling elderly population. , 1993, Journal of gerontology.

[9]  Per Magne Ueland,et al.  Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. , 2002, JAMA.

[10]  C. Dufouil,et al.  Homocysteine, white matter hyperintensities, and cognition in healthy elderly people , 2003, Annals of neurology.

[11]  Massey Jt,et al.  Design and estimation for the National Health Interview Survey 1985-94. , 1989 .

[12]  I. Rosenberg,et al.  B vitamins, homocysteine, and neurocognitive function in the elderly. , 2000, The American journal of clinical nutrition.

[13]  B. Winblad,et al.  Cobalamin Levels Are Not Reduced in Alzheimer's Disease: Results from a Population‐Based Study , 1994, Journal of the American Geriatrics Society.

[14]  M. Albert,et al.  High, usual and impaired functioning in community-dwelling older men and women: findings from the MacArthur Foundation Research Network on Successful Aging. , 1993, Journal of clinical epidemiology.

[15]  B. Winblad,et al.  Risk factors for late‐ onset Alzheimer's disease: A population‐ based, case‐control study , 1993, Annals of neurology.

[16]  V. Herbert,et al.  Staging vitamin B-12 (cobalamin) status in vegetarians. , 1994, The American journal of clinical nutrition.

[17]  M. Mattson,et al.  Folic Acid Deficiency and Homocysteine Impair DNA Repair in Hippocampal Neurons and Sensitize Them to Amyloid Toxicity in Experimental Models of Alzheimer's Disease , 2002, The Journal of Neuroscience.

[18]  Roberta F. White,et al.  The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort. , 2000, Archives of neurology.

[19]  M. Albert,et al.  Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease. , 1991, The International journal of neuroscience.

[20]  J. Zhang,et al.  What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. , 1998, JAMA.

[21]  T. Tamura,et al.  Inhibition of EDTA of growth of Lactobacillus casei in the folate microbiological assay and its reversal by added manganese or iron. , 1990, Clinical chemistry.

[22]  E. Kaplan,et al.  The assessment of aphasia and related disorders , 1972 .

[23]  Sudha Seshadri,et al.  Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease , 2002 .

[24]  A. Omran,et al.  The epidemiologic transition. A theory of the Epidemiology of population change. 1971. , 2001, Bulletin of the World Health Organization.

[25]  H. Crystal,et al.  Serum Vitamin B12 Levels and Incidence of Dementia in a Healthy Elderly Population: A Report from the Bronx Longitudinal Aging Study , 1994, Journal of the American Geriatrics Society.

[26]  C. Culmsee,et al.  Homocysteine Elicits a DNA Damage Response in Neurons That Promotes Apoptosis and Hypersensitivity to Excitotoxicity , 2000, The Journal of Neuroscience.

[27]  Vernon,et al.  Radioenzymatic assay for direct measurement of plasma pyridoxal 5'-phosphate. , 1983, Clinical chemistry.

[28]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[29]  Y. Sako,et al.  Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. , 1987, Journal of chromatography.

[30]  W. Markesbery,et al.  Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun study. , 2000, The American journal of clinical nutrition.

[31]  J W Rowe,et al.  Predicting changes in physical performance in a high-functioning elderly cohort: MacArthur studies of successful aging. , 1994, Journal of gerontology.

[32]  R. Hales,et al.  J Neuropsychiatry Clin Neurosci , 1992 .

[33]  S. Z. Nagi.  An epidemiology of disability among adults in the United States. , 1976, The Milbank Memorial Fund quarterly. Health and society.

[34]  E. Pfeiffer.  A Short Portable Mental Status Questionnaire for the Assessment of Organic Brain Deficit in Elderly Patients † , 1975, Journal of the American Geriatrics Society.

[35]  C. DeCarli,et al.  Head injury and the risk of AD in the MIRAGE study , 2000, Neurology.

[36]  D. Drachman,et al.  Apolipoprotein E ε4 allele and the lifetime risk of Alzheimer's disease : what physicians know, and what they should know , 1995 .

[37]  M. Soyka,et al.  Dementia Associated With Vitamin B12 Deficiency , 2000 .

[38]  K. Pettigrew,et al.  The natural history of homocystinuria due to cystathionine beta-synthase deficiency. , 1985, American journal of human genetics.

[39]  J. Deijen,et al.  Vitamin B-6 supplementation in elderly men: effects on mood, memory, performance and mental effort , 2005, Psychopharmacology.

[40]  B. Winblad,et al.  Vitamin B12 and folate in relation to the development of Alzheimer’s disease , 2001, Neurology.